Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$110.67 +2.8%	$106.39	$66.01 ▼ $119.96	$137.67B	0.29	7.65 million shs	19.54 million shs
LLY Eli Lilly and Company	$776.18 -2.4%	$780.19	$677.09 ▼ $972.53	$735.61B	0.41	3.67 million shs	4.11 million shs
MDT Medtronic	$86.19 +0.0%	$84.82	$75.96 ▼ $96.25	$110.54B	0.79	6.94 million shs	10.13 million shs
PFE Pfizer	$24.20 -0.2%	$23.46	$20.92 ▼ $31.54	$137.56B	0.57	41.21 million shs	39.50 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	0.00%	+2.00%	+0.29%	-1.23%	+61.30%
LLY Eli Lilly and Company	0.00%	+1.67%	+5.13%	-5.97%	-14.27%
MDT Medtronic	0.00%	-0.12%	+3.81%	-4.15%	+9.51%
PFE Pfizer	0.00%	+0.95%	+3.14%	-4.57%	-13.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GILD Gilead Sciences	4.7809 of 5 stars	1.4	3.0	4.2	4.1	3.5	2.5	3.1
LLY Eli Lilly and Company	4.9852 of 5 stars	4.4	4.0	3.3	4.0	2.8	1.7	1.9
MDT Medtronic	4.8824 of 5 stars	3.3	3.0	3.3	4.0	3.5	1.7	1.9
PFE Pfizer	4.8654 of 5 stars	2.3	3.0	4.2	4.3	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	-0.11% Downside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,011.61	30.33% Upside
MDT Medtronic	2.67	Moderate Buy	$97.87	13.54% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.54% Upside

Current Analyst Ratings Breakdown

Latest GILD, MDT, PFE, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/16/2025	MDT Medtronic	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	MDT Medtronic	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$110.00
6/6/2025	MDT Medtronic	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/22/2025	MDT Medtronic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$100.00 ➝ $98.00
5/22/2025	MDT Medtronic	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$105.00 ➝ $101.00
5/22/2025	MDT Medtronic	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$94.00 ➝ $92.00
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/19/2025	MDT Medtronic	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GILD Gilead Sciences	$28.75B	4.79	$6.87 per share	16.11	$15.44 per share	7.17
LLY Eli Lilly and Company	$45.04B	16.33	$14.25 per share	54.48	$15.03 per share	51.64
MDT Medtronic	$33.54B	3.30	$7.77 per share	11.10	$37.62 per share	2.29
PFE Pfizer	$63.63B	2.16	$4.37 per share	5.54	$15.62 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GILD Gilead Sciences	$480M	$4.75	23.30	13.65	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	63.16	24.94	1.13	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
MDT Medtronic	$4.66B	$3.62	23.81	14.78	2.32	13.90%	14.54%	7.83%	8/19/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.53	7.99	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest GILD, MDT, PFE, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q4 2025	MDT Medtronic	$1.58	$1.62	+$0.04	$0.82	$8.81 billion	$8.93 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GILD Gilead Sciences	$3.16	2.86%	N/A	66.53%	10 Years
LLY Eli Lilly and Company	$6.00	0.77%	N/A	48.82%	11 Years
MDT Medtronic	$2.84	3.29%	N/A	78.45%	49 Years
PFE Pfizer	$1.72	7.11%	N/A	124.64%	16 Years

Latest GILD, MDT, PFE, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/21/2025	MDT Medtronic	quarterly	$0.71	3.3%	6/27/2025	6/27/2025	7/11/2025
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GILD Gilead Sciences	1.16	1.37	1.23
LLY Eli Lilly and Company	2.18	1.37	1.06
MDT Medtronic	0.53	1.85	1.42
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GILD Gilead Sciences	83.67%
LLY Eli Lilly and Company	82.53%
MDT Medtronic	82.06%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
GILD Gilead Sciences	0.27%
LLY Eli Lilly and Company	0.14%
MDT Medtronic	0.20%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.41 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

GILD, MDT, PFE, and LLY Headlines

Recent News About These Companies

Brokerages Set Pfizer Inc. (NYSE:PFE) PT at $29.17

4 hours ago | americanbankingnews.com

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

June 29 at 10:14 PM | investing.com

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

June 29 at 9:23 PM | prnewswire.com

Essex Financial Services Inc. Sells 31,049 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 7:23 AM | marketbeat.com

KBC Group NV Purchases 199,736 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 7:07 AM | marketbeat.com

Cohen Investment Advisors LLC Grows Stake in Pfizer Inc. (NYSE:PFE)

June 29 at 6:33 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 29 at 5:05 AM | marketbeat.com

Creative Financial Designs Inc. ADV Sells 32,370 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 4:16 AM | marketbeat.com

GAMMA Investing LLC Acquires 25,785 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 3:03 AM | marketbeat.com

Pfizer’s HYMPAVZI Shows Superiority in Hemophilia A/B with Inhibitors in Phase 3 Study

June 29 at 2:17 AM | insidermonkey.com

Pfizer’s Bold Clinical Trials Could Boost Stock Performance

June 28 at 11:25 AM | tipranks.com

Sumitomo Mitsui Trust Group Inc. Sells 941,490 Shares of Pfizer Inc. (NYSE:PFE)

June 28 at 8:17 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Sunbelt Securities Inc.

June 28 at 6:56 AM | marketbeat.com

Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment

June 28 at 6:38 AM | msn.com

3 No-Brainer Stocks to Buy for Under $100 Right Now

June 28 at 6:35 AM | fool.com

BSW Wealth Partners Acquires 17,274 Shares of Pfizer Inc. (NYSE:PFE)

June 28 at 6:30 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by QSM Asset Management Ltd

June 28 at 5:44 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Achmea Investment Management B.V.

June 28 at 5:26 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Illinois Municipal Retirement Fund

June 28 at 5:17 AM | marketbeat.com

Perpetual Ltd Grows Stake in Pfizer Inc. (NYSE:PFE)

June 28 at 4:46 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Holdings Lifted by Bessemer Group Inc.

June 28 at 4:03 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Texas Instruments Stock: Congress Likes It, Should You Too?
By Thomas Hughes | June 24, 2025
View Texas Instruments Stock: Congress Likes It, Should You Too?
Could Meta and Eli Lilly Trigger the Next Stock Split Boom?
By Leo Miller | June 16, 2025
View Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

GILD, MDT, PFE, and LLY Company Descriptions

Gilead Sciences NASDAQ:GILD

$110.67 +3.05 (+2.83%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$110.86 +0.19 (+0.17%)

As of 05:56 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Eli Lilly and Company NYSE:LLY

$776.18 -18.94 (-2.38%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$777.99 +1.81 (+0.23%)

As of 05:57 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic NYSE:MDT

$86.19 +0.01 (+0.01%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$86.55 +0.36 (+0.42%)

As of 05:14 AM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Pfizer NYSE:PFE

$24.20 -0.04 (-0.18%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$24.24 +0.04 (+0.16%)

As of 05:56 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time